Private equity acquires a taste for drug development
By David Carnevali (Reuters) - Private equity firms that deemed drug development too risky for their liking in the past are increasingly investing in ...
Source: whbl.com
Page 31 - Sofinnova Partners News Today : Breaking News, Live Updates & Top Stories | Vimarsana
Stay updated with breaking news from Sofinnova Partners. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.
Top News In Sofinnova Partners Today - Breaking & Trending Today
Investegate |Amolyt Pharma Announcements | Amolyt Pharma: Amolyt Pharma Announces $138 Million Series C Financing led by Sofinnova Partners and co-led by Intermediate Capital Group
Investegate announcements from Amolyt Pharma, Amolyt Pharma Announces $138 Million Series C Financing led by Sofinnova Partners and co-led by Intermediate Capital Group
Source: investegate.co.uk
Amolyt Pharma Announces $138 Million Series C Financing led by Sofinnova Partners and co-led by Intermediate Capital Group
Funds will be used to complete phase 3 clinical development of eneboparatide (AZP-3601) for hypoparathyroidism, and advance AZP-3813 into the clinic for acromegalyLYON, France and CAMBRIDGE, Mass., Jan.
Source: finanznachrichten.de
Mission Therapeutics Successfully Completes First Clinical Assessment for Lead DUB Program, MTX652
Safety, tolerability and pharmacokinetic endpoints successfully met Follow-on clinical trials to be initiated in 2023 Mission Therapeutics ("Mission"), a drug discovery and development
Source: finanznachrichten.de
Sofinnova Partners Welcomes Mano Iyer as Venture Partner
Sofinnova Partners ("Sofinnova"), a leading European life sciences venture capital firm based in Paris, London, and Milan, announced the appointment of Manohar (Mano) Iyer, a serial entrepreneur with
Source: finanznachrichten.de